BYSI - NASDAQ
BeyondSpring Inc.
$1.71
+4.9%BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
At a Glance
Live SnapshotBeyondSpring Inc. Profit Bridge
Profitability Analysis
BeyondSpring Inc. Income Statement
BYSI • NASDAQ
| BeyondSpring Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
0.0 | 0.0 | 0.0 | 1.4M | 1.4M | 180K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||
(87K) | (0.0) | (302K) | (0.0) | (0.0) | (0.0) | (77K) | (48K) | (32K) | (18K) | (10K) | (0.0) | |
-87K | 0.0 | -302K | 1.4M | 1.4M | 180K | -77K | -48K | -32K | -18K | -10K | 0.0 | |
OPERATING INCOME | ||||||||||||
(8.9M) | (8.8M) | (14.8M) | (38.6M) | (67.6M) | (64.4M) | (40.3M) | (57.5M) | (98M) | (12.4M) | (7.5M) | (2.1M) | |
(4.6M) | (6.1M) | (7.5M) | (13M) | (30.7M) | (22.6M) | (9M) | (5.9M) | (9.1M) | (1.9M) | (1.2M) | (233K) | |
(4.4M) | (2.6M) | (7.3M) | (25.6M) | (36.9M) | (41.8M) | (31.3M) | (51.6M) | (88.9M) | (10.4M) | (6.3M) | (1.9M) | |
-8.9M | -8.8M | -15.1M | -37.2M | -66.2M | -64.2M | -40.3M | -57.5M | -98M | -12.4M | -7.5M | -2.1M | |
PRE-TAX INCOME | ||||||||||||
(0.0) | (0.0) | (0.0) | (17K) | (87K) | (85K) | (206K) | (0.0) | (0.0) | (177K) | (532K) | (826K) | |
78K | 59K | 421K | 178K | 11K | 31K | -22K | 211K | 120K | -159K | -519K | -823K | |
-87K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (315K) | (918K) | (0.0) | (0.0) | (0.0) | |
320K | -15K | 1.2M | 1.1M | 1.6M | 390K | -26K | 71K | 1.6M | -177K | -577K | -904K | |
-8.6M | -8.8M | -13.9M | -36.1M | -64.6M | -63.8M | -40.3M | -57.5M | -96.4M | -12.5M | -8.1M | -3M | |
NET INCOME | ||||||||||||
(90K) | (96K) | (92K) | (163K) | (3.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (495K) | (0.0) | |
-8M | -11.1M | -21M | -33.3M | -64.2M | -61M | -38.3M | -54.9M | -91.8M | -12M | -8M | -3M |
SEC Filings
BYSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 17, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 23, 2025 | September 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 16, 2025 | September 15, 2025 | 2025 |
Related Guides
Continue your BYSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.